Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) SVP Gunther Birznieks sold 8,568 shares of the company’s stock in a transaction dated Tuesday, January 2nd. The stock was sold at an average price of $15.26, for a total transaction of $130,747.68. Following the completion of the transaction, the senior vice president now owns 118,366 shares of the company’s stock, valued at approximately $1,806,265.16. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Vanda Pharmaceuticals Inc. (VNDA) traded down $0.05 on Thursday, hitting $15.55. 385,547 shares of the company traded hands, compared to its average volume of 468,449. Vanda Pharmaceuticals Inc. has a 52-week low of $11.90 and a 52-week high of $18.99. The firm has a market cap of $698.62, a P/E ratio of -48.59 and a beta of 1.29.

Vanda Pharmaceuticals (NASDAQ:VNDA) last released its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.10) earnings per share for the quarter, hitting the consensus estimate of ($0.10). Vanda Pharmaceuticals had a negative net margin of 9.01% and a negative return on equity of 10.99%. The firm had revenue of $41.30 million during the quarter, compared to the consensus estimate of $43.90 million. During the same quarter in the prior year, the firm earned ($0.01) EPS. The company’s revenue for the quarter was up 7.3% on a year-over-year basis. analysts predict that Vanda Pharmaceuticals Inc. will post -0.44 earnings per share for the current year.

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Legal & General Group Plc raised its position in shares of Vanda Pharmaceuticals by 37.4% during the 2nd quarter. Legal & General Group Plc now owns 11,105 shares of the biopharmaceutical company’s stock worth $181,000 after purchasing an additional 3,022 shares during the last quarter. Kopp Investment Advisors LLC acquired a new position in shares of Vanda Pharmaceuticals during the 2nd quarter worth about $196,000. Los Angeles Capital Management & Equity Research Inc. acquired a new position in shares of Vanda Pharmaceuticals during the 3rd quarter worth about $277,000. Voya Investment Management LLC raised its position in shares of Vanda Pharmaceuticals by 29.7% during the 2nd quarter. Voya Investment Management LLC now owns 20,118 shares of the biopharmaceutical company’s stock worth $328,000 after purchasing an additional 4,605 shares during the last quarter. Finally, Dynamic Technology Lab Private Ltd raised its position in shares of Vanda Pharmaceuticals by 46.3% during the 2nd quarter. Dynamic Technology Lab Private Ltd now owns 20,510 shares of the biopharmaceutical company’s stock worth $335,000 after purchasing an additional 6,487 shares during the last quarter. Hedge funds and other institutional investors own 88.43% of the company’s stock.

A number of brokerages have weighed in on VNDA. BidaskClub upgraded shares of Vanda Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, December 22nd. ValuEngine upgraded shares of Vanda Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, December 20th. Oppenheimer reiterated a “buy” rating and issued a $25.00 price objective on shares of Vanda Pharmaceuticals in a research report on Sunday, November 12th. Zacks Investment Research downgraded shares of Vanda Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, October 26th. Finally, Piper Jaffray Companies set a $26.00 price objective on shares of Vanda Pharmaceuticals and gave the stock a “buy” rating in a research report on Thursday, October 19th. Three equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Vanda Pharmaceuticals has a consensus rating of “Buy” and an average price target of $21.50.

ILLEGAL ACTIVITY NOTICE: This report was first published by American Banking News and is the property of of American Banking News. If you are accessing this report on another domain, it was illegally copied and republished in violation of US and international trademark & copyright legislation. The correct version of this report can be viewed at https://www.americanbankingnews.com/2018/01/04/vanda-pharmaceuticals-inc-vnda-svp-sells-130747-68-in-stock.html.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).

Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.